NAT-8L Inhibitors
NAT-8L inhibitors belong to a specific chemical class that plays a crucial role in modulating biological processes within living organisms. The term NAT-8L stands for N-acetyltransferase 8-like, which refers to a subtype of enzymes involved in acetylation reactions. These inhibitors are designed to selectively target NAT-8L enzymes, thereby influencing the acetylation of certain substrates. Acetylation is a fundamental biochemical process where an acetyl group is transferred from one molecule to another, often serving as a regulatory mechanism for various cellular functions.
The molecular structure of NAT-8L inhibitors is intricately designed to interact with the active sites of the NAT-8L enzymes, disrupting their normal enzymatic activity. By doing so, these inhibitors can modulate the acetylation patterns of specific molecules, leading to downstream effects on cellular processes. The specificity of NAT-8L inhibitors makes them valuable tools in elucidating the intricate network of acetylation reactions within cells, contributing to a deeper understanding of molecular pathways and potential targets for intervention. Researchers are actively exploring the implications of NAT-8L inhibitors in the context of cellular homeostasis and signaling, shedding light on their role in fundamental biological processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Methotrexate is a dihydrofolate reductase inhibitor that blocks the synthesis of thymidylate, purine nucleotides, and the amino acid methionine, which requires the cofactor tetrahydrofolate, leading to inhibition of cell division. Since NAT-8L is involved in the metabolism of amino acids, methotrexate could decrease the availability of substrates necessary for NAT-8L activity. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide is a protein synthesis inhibitor, acting by interfering with the translocation step in protein synthesis, thus preventing the growth of cells. Inhibiting protein synthesis can indirectly reduce NAT-8L levels by preventing its translation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which play a key role in signaling pathways involved in cell growth and survival. Inhibition of PI3K can lead to a reduction in cell growth, potentially reducing the demand for amino acid metabolism where NAT-8L is involved. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that interrupts the mTOR signaling pathway, a central regulator of cell growth and metabolism. This can reduce protein synthesis and amino acid metabolism, thereby potentially decreasing NAT-8L activity due to lower substrate levels. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-kinase inhibitor with effects on cell proliferation and angiogenesis. By inhibiting multiple kinases, it may alter signaling pathways that indirectly reduce the expression or activity of NAT-8L. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
5-Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase, leading to a decrease in DNA synthesis. This can cause a decrease in cell proliferation, which may indirectly lead to reduced NAT-8L function as cell demand for amino acid metabolism decreases. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
Doxorubicin intercalates DNA and inhibits topoisomerase II, which can lead to apoptosis and a decrease in cell proliferation. This may result in reduced NAT-8L activity due to decreased cell turnover and metabolic demand. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $199.00 $599.00 | 24 | |
GW4869 is a neutral sphingomyelinase inhibitor, which can impact sphingolipid metabolism. As sphingolipids are involved in cellular signaling, their altered metabolism could influence pathways that indirectly modulate NAT-8L activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that leads to the accumulation of misfolded proteins, inducing cell stress and potentially altering metabolic pathways that include NAT-8L activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the MAPK/ERK pathway, a key signaling mechanism in cell growth and differentiation. This may indirectly reduce NAT-8L activity by affecting cellular metabolism and growth signals. | ||||||